Nektar Update (1-18-13)

CONTINUED PROGRESS AND PIPELINE VISIBILITY. Nektar management continues to make progress across its late–stage development pipeline, relieving some investor concern for the naloxegol (NKTR-118) program – NKTR’s lead compound – under development for the treatment of opioid-induced constipation (OIC).  With renewed optimism on the ‘118 program and upcoming related catalysts, increasing appreciation of the breadth[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.